AV 7909

Drug Profile

AV 7909

Alternative Names: AV7909; BioThrax + agatolimod; NuThrax; Third-generation anthrax vaccine candidate (BioThrax + CPG 7909) - Emergent BioSolutions

Latest Information Update: 15 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Emergent BioSolutions
  • Class Anthrax vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Anthrax

Most Recent Events

  • 04 May 2017 Emergent Biosolutions plans a phase III trial for Anthrax
  • 30 Sep 2016 Emergent Biosolutions receives BARDA contract valued at $US1.6 billion for AV 7909
  • 04 Aug 2016 Emergent BioSolutions submits a proposal to the US Department of Health and Human Services recommending AV 7909 as a next generation anthrax vaccine for post-exposure prophylaxis of Anthrax
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top